How Regional Sites in a Global Site Network Combine Local Insight with Global Scale

The number of clinical trials registered in the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) has expanded dramatically over the past 25 years. Registrations rose from 5,349 in 1999 to a cumulative total of more than 1,000,000 by 2024, with particularly rapid growth occurring during the past decade as annual trial registrations reached nearly 40,000.¹ While trials have historically been concentrated in the United States, China, India, Japan, Germany, the United Kingdom, and France (collectively accounting for more than 662,000 studies), clinical research activity now spans every region of the world, with particularly strong growth in the Western Pacific and Southeast Asia.²

At the same time, the nature of clinical research has become far more complex. Trials increasingly involve advanced therapy medicinal products, novel delivery systems, and targeted treatments for rare diseases affecting small, geographically dispersed patient populations. Sponsors are also adopting new study designs, including adaptive and virtual trials, along with more sophisticated endpoints and diagnostic tools. Greater emphasis on enrolling diverse patient populations has added further operational considerations. These changes have become so pronounced that researchers recently proposed a formal metric, the Trial Complexity Score, to quantify them.³ An analysis of 16,790 trials conducted since 2010 found that complexity has risen substantially across therapeutic areas and all phases of clinical development.

These shifts place significant operational pressure on clinical sites. Studies now often require coordination across numerous sites and countries while also managing increasingly intricate protocols and data requirements. Recruitment and retention have become more difficult, and costs have climbed. Investigators, clinical staff and trial participants face greater procedural burdens as protocols incorporate more assessments, biomarkers, and monitoring requirements.

The evolving clinical research landscape has also coincided with a surge in emerging biotechnology companies, which now account for a growing share of clinical trial activity and early-stage innovation.⁴ Many of these organizations focus on advancing promising therapeutic concepts through early clinical development before partnering with larger pharmaceutical companies or exiting, but they often lack the internal infrastructure required to manage complex global trials. As a result, they rely heavily on contract research organizations (CROs) and other external partners for both operational execution and strategic guidance throughout study design and implementation.⁵

In response, the clinical research industry has increasingly turned to integrated global site networks. By linking multiple clinical sites through shared operational standards, governance structures, and data systems, these networks help sponsors manage multi-site studies more efficiently while maintaining consistency in study conduct and data quality. In doing so, they provide a practical framework for executing complex global trials and reducing the operational burden that accompanies modern clinical research.⁶

As site networks become more central to clinical development, sponsors must evaluate them according to more than geographic footprint. The size of a network matters, but scale alone does not ensure successful execution. An effective global site network partner should combine standardized processes, strong quality oversight, proven site relationships, therapeutic expertise, and the flexibility to adapt study execution to local clinical realities.

At a basic level, sponsors should look for networks with sites that have been carefully vetted for quality, infrastructure, regulatory readiness, and operational consistency. This includes the ability to apply common standards across owned sites, partner sites, and affiliated clinical research units. Sponsors should also assess whether the network supports consistent protocol-specific training, data collection, monitoring practices, and reporting expectations across multiple geographies.

Local relevance is equally important. Clinical trial protocols must be executed consistently, but each region has its own regulatory landscape, clinical infrastructure, physician referral patterns, and patient access dynamics. A strong network partner should understand these differences and help sponsors select sites based not only on country or cost but also on therapeutic expertise, patient availability, investigator experience, and local healthcare relationships.

The most effective global site networks reconcile these priorities by combining centralized coordination with local clinical engagement. Shared operating standards provide consistency, while site-level expertise helps adapt execution to the realities of each patient population and healthcare community. This balance is especially important as sponsors pursue studies involving rare diseases, specialized procedures, complex biomarkers, or populations that are difficult to identify and enroll.

Global clinical trials require consistency. Sponsors need confidence that study conduct, data collection, monitoring, and reporting will remain aligned across countries and sites. Without that consistency, variability in execution may complicate data interpretation, delay decision-making, and add unnecessary burden to study teams.

However, standardization should not mean rigidity. Sites operate within different healthcare systems and patient communities, and successful execution often depends on understanding local referral pathways, clinician relationships, staffing models, and cultural expectations around research participation. A network partner that imposes uniform processes without accounting for these factors may miss opportunities to improve recruitment, retention, and patient experience.

The ideal model combines a unified governance and quality framework with site-level flexibility. Common standards, templates, and workflows should ensure consistency across the network, but those tools should be reviewed and refined to remain practical, purposeful, and focused on study execution. Processes that add administrative burden without improving quality can slow studies and frustrate sites.

This balance is particularly important in hub-and-spoke models, where high-capacity clinical research units serve as central hubs for patient domiciling, complex procedures, and intensive study activities, while affiliated physician practices and specialty clinics expand the network’s reach into local healthcare communities. In well-designed models, these relationships give sponsors access to broader patient populations and clinical expertise while preserving local trust and continuity of care.

When a global site network is implemented effectively, sponsors gain several important operational advantages. Standardized data collection, uniform monitoring strategies, and established reporting practices ensure that studies are conducted consistently across sites. This uniformity reduces variability in study execution and helps produce more reliable, comparable data across regions and patient populations.

Network coordination also facilitates communication among investigators. Sites participating in the same study remain connected through shared operational platforms and oversight structures, allowing investigators to exchange insights about protocol implementation, recruitment strategies, and operational challenges as they arise. This collaborative environment improves study execution across the network, as lessons learned at one site are quickly shared with other sites.

By working with a coordinated site network, sponsors also benefit from more efficient site identification and selection. Because sites within the network have already been vetted for quality, infrastructure and regulatory readiness, feasibility assessments may be conducted quickly. Sponsors can often receive site recommendations and enrollment projections within days and through a single point of contact, allowing studies to move from protocol planning to site activation much faster than when individual sites must be identified and evaluated independently. The result is a more streamlined study startup process that saves both time and cost while maintaining consistent quality standards.

Patient access depends heavily on local clinical relationships. Even when a trial is part of a global development program, patients often learn about research opportunities through physicians and healthcare providers they already know and trust. As a result, effective site network partners should demonstrate how they build relationships with local physicians, specialists, advocacy groups, and community organizations.

These relationships make clinical research more accessible and more familiar. When local providers understand the studies available through a research network, they can identify patients who may benefit from investigational therapies while continuing to provide ongoing care. This arrangement helps preserve the physician–patient relationship while creating a pathway into research participation.

The model is especially valuable for physicians who care for patients who may benefit from clinical research but who do not have the infrastructure to conduct trials within their own practices. Some specialists may lack the facilities, staffing, or procedural capacity needed for complex protocols involving overnight domiciling, intensive monitoring, or frequent procedures. In those cases, a dedicated research site provides support for trial conduct while allowing the referring physician to remain involved in the patient’s long-term care.

Over time, these partnerships help normalize clinical research within local healthcare ecosystems. Physicians become familiar with the types of studies being conducted and the resources available through the research site, while patients gain opportunities to access emerging therapies without leaving the care networks they trust. In this way, clinical trials can become more closely integrated with routine clinical practice rather than existing as a separate and unfamiliar system.

Community-Based Physician Engagement

Within the Trialmed site network, individual clinics maintain relationships with local physicians and specialists to connect patients with appropriate research opportunities. In some U.S. markets, for example, dermatology practices may regularly participate in late-phase outpatient studies but may not have the infrastructure required for more procedurally demanding protocols. Dedicated early development clinics can support those activities, allowing physicians to maintain primary clinical relationships with their patients while expanding access to studies that require more intensive monitoring or clinical infrastructure.

Similar referral relationships support specialists who do not conduct research within their own practices. HIV clinicians, for instance, may care for patients interested in new treatment options, such as monoclonal antibodies or long-acting injectables, but may not have the staffing or facilities required to run clinical trials themselves. In these situations, established relationships with research sites can help connect eligible patients with ongoing studies while preserving continuity of care.

A global site network that combines standardized operational practices with diverse clinical specialties is well positioned to meet the needs of both sponsors and patients. Early involvement in clinical trial planning is essential so that practical clinical insight can inform protocol development from the outset. By connecting subject matter experts with sponsor teams and their key opinion leaders, the network helps ensure that study designs minimize complexity and reflect real-world clinical practice.

This early collaboration is particularly important because many protocols originate in academic or scientific settings where operational feasibility and patient burden may not be fully considered. When experienced investigators participate in protocol discussions early in the process, they can help shape study schedules, procedures and endpoints in ways that remain scientifically rigorous while also making participation realistic and attractive for patients and manageable for study sites.

The result is a protocol that still delivers the high-quality data sponsors require but avoids unnecessary complexity that may discourage participation or slow enrollment. Studies designed with these considerations in mind tend to recruit more effectively and run more efficiently across participating sites, ultimately resulting in cost savings for study sponsors.

Sponsors frequently welcome this type of practical input. In some cases, clinical experts contribute during the early planning stages of a new study. In others, they are asked to evaluate trials that may have struggled to enroll participants at other sites and identify opportunities to improve efficiency and feasibility. In both situations, incorporating operational and patient-centered perspectives can help improve feasibility and restore momentum to a study.

As more clinical trials target rare diseases that affect small, geographically dispersed patient populations, sponsors and research sites must find new ways to identify and support eligible participants. Even a large global network cannot place clinical sites within easy reach of every patient. Site network partners increasingly need decentralized capabilities that extend recruitment, screening, and follow-up beyond the immediate vicinity of individual research locations.

A concierge-style approach can help address these challenges by combining centralized recruitment with decentralized clinical services, including access to home healthcare solutions. For rare disease indications, for example, research teams may conduct broad outreach to identify potential participants for highly specialized studies. Initial engagement can take place through virtual conversations that allow investigators to educate prospective patients about the trial and answer questions related to study participation.

Electronic consent may then be completed remotely, followed by coordination with the patient’s existing healthcare provider to confirm diagnoses, collect medical records, and complete preliminary laboratory testing to assess eligibility. Once appropriate candidates are identified, concierge services support travel to a participating site for final screening and enrollment. After enrollment and any associated domiciling for complex or invasive procedures, many aspects of the study continue closer to the patient’s home through home healthcare services and decentralized trial capabilities.

By extending recruitment beyond the immediate vicinity of individual sites, this approach allows sponsors and sites to reach deeper into communities and seek appropriate patients rather than only those who happen to live near a study location. The model also enables expanded access to diverse patient populations in rural or underserved areas that historically have had limited opportunities to participate in clinical research.

As clinical trials become more international, regional hubs are becoming increasingly important to global development strategy. Sponsors may need early-phase capacity in one region, later-phase enrollment support in another and access to patient populations across multiple countries. A modern site network partner should be able to help sponsors assess these options and identify development pathways that align scientific, operational, and geographic priorities.

Regional hubs provide a practical bridge between local expertise and multinational execution. A well-positioned hub may support early-phase studies, specialized procedures, or intensive monitoring while also connecting to a broader network of affiliated sites that can support later-stage development. This allows sponsors to begin a program in one location and expand into additional geographies as clinical needs evolve.

For sponsors, the value of a regional hub lies not only in facility capacity but also in the surrounding network. Site partners should be able to provide insight into regional feasibility, investigator capabilities, enrollment expectations, regulatory considerations, and cost differences. This information enables sponsors to compare development strategies across regions and choose study locations based on a more complete understanding of operational fit.

Prague as a Central European Early-Phase Hub

The Prague, Czech Republic, site within the Trialmed network illustrates how a regional hub supports broader European development strategies. The site has operated as a late-phase clinical research center since 2018 and has conducted approximately 30 studies to date. Its expansion to include dedicated Phase I capabilities positions Prague as a fully integrated clinical research center capable of supporting studies across multiple stages of development.

The facility includes a dedicated 15-bed Phase I clinical research unit designed to support early development programs, including first-in-human studies, multi-cohort trials, and other complex early-phase protocols. For sponsors seeking European early-phase capacity, Prague offers access to a strategically located Central European research center with strong clinical expertise, relatively lower operating costs and less competition for early-phase trial capacity than many larger Western European and U.S. markets.

The Prague expansion also strengthens the role of regional networks in clinical development. Sponsors conducting early-phase studies in Prague may be able to scale programs into additional Trialmed-affiliated sites across Central and Eastern Europe as development progresses. This creates a pathway for expanding enrollment, accessing additional patient populations, and supporting later-stage development within a coordinated regional framework.

The growing complexity of clinical research has made site network selection a strategic decision. Sponsors need partners that can do more than provide access to a list of sites. They need networks capable of combining operational consistency, local clinical relationships, therapeutic expertise and flexible patient access strategies across multiple regions.

The strongest site network partners bring structure to global trial execution while preserving the local insight that makes recruitment, retention, and patient engagement possible. They support quality and data consistency through shared standards, help sponsors evaluate feasibility early, connect trials to everyday clinical care, and expand access through decentralized services and regional hubs.

As clinical development becomes more geographically distributed and operationally complex, global site networks will play an increasingly important role in connecting sponsors, investigators, and patients. Networks that align global execution with local clinical reality will be best positioned to support efficient studies, high-quality data generation, and broader access to clinical research.

1. “Number of clinical trial registrations by location, disease, phase of development, age and sex of trial participants (1999–2025).” World Health Organization. Accessed 9 Apr. 2026.

2. “Number of clinical trials by year, country, WHO region and income group (1999–2025).” World Health Organization. Accessed 9 Apr. 2026.

3. Markey, Nigel, et al. “Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials.” Sci. Rep. 14: 3514 (2024).

4. Ellsworth, Gary. “CRO Industry Trends for 2025.” Contract Pharma. 25 Aug. 2025.

5. Bleys, Joachim, et al. “CROs and biotech companies: Fine-tuning the partnership.” McKinsey. 9 Jun. 2022.

6. Gallagher, Gerri, et al. “The Strategic Emergence of Site Networks in Clinical Research.” Applied Clinical Trials. 14 Oct. 2024.